A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Pharmacokinetic Profile of RSS0393 Ointment as a Single and Multiple Dose Ascending Local Dermal Administration in Healthy and Adult Subjects With Psoriasis
Latest Information Update: 09 May 2025
At a glance
- Drugs RSS 0393 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 02 May 2025 Planned End Date changed from 1 Oct 2024 to 1 Dec 2025.
- 02 May 2025 Planned primary completion date changed from 1 Aug 2024 to 1 Dec 2025.
- 02 May 2025 Status changed from not yet recruiting to active, no longer recruiting.